sintilimab + interleukin-2 + capecitabine + oxaliplatin

Based on the provided search results, the combination of sintilimab with oxaliplatin and capecitabine (CapeOx) is discussed as a first-line treatment for gastric/gastroesophageal junction adenocarcinoma based on a phase Ib clinical trial. Sintilimab is a PD-1 inhibitor [1, 2]. Oxaliplatin is a platinum-based chemotherapy agent [4, 5]. Capecitabine is an oral prodrug converted to 5-fluorouracil, an antimetabolite [5]. The search results explicitly state that there is no specific mention or information available regarding the exact four-drug combination that includes interleukin-2 [text]. Therefore, detailed information on the efficacy, safety, dosage, or development status of 'sintilimab + interleukin-2 + capecitabine + oxaliplatin' is not available from the provided text.